Rekombinanter SATB2 Antikörper (AA 150-350)
Kurzübersicht für Rekombinanter SATB2 Antikörper (AA 150-350) (ABIN7870945)
Target
Alle SATB2 Antikörper anzeigenAntikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 150-350
-
Verwendungszweck
- SATB2 Antibody
-
Aufreinigung
- Protein A/G affinity
-
Immunogen
- A recombinant partial protein sequence (within amino acids 150-350) from the human protein was used as the immunogen for the SATB2 antibody.
-
Isotyp
- IgG, kappa
-
-
-
-
Applikationshinweise
- Optimal dilution of the SATB2 antibody should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Aliquot the SATB2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- SATB2 (SATB Homeobox 2 (SATB2))
-
Andere Bezeichnung
- SATB2
-
Hintergrund
- SATB2 is a DNA binding protein that specifically binds nuclear matrix attachment regions. It is involved in transcription regulation and chromatin remodeling. SATB2 expression in colorectal carcinomas (CRC) is correlated with good prognosis and in laryngeal squamous cell carcinoma it functions as a tumor suppressor wherein loss of expression is positively correlated with high tumor grade and recurrence. Moreover, SATB2, in combination with CK20, could identify almost all CRC s. Upper gastrointestinal (GI) carcinomas and pancreatic ductal carcinomas are usually negative for SATB2, and ovarian carcinomas, lung adenocarcinomas, and adenocarcinomas from other origin are rarely positive for SATB2. Additionally, SATB2 antibody can identify neuroendocrine neoplasms of colon and rectum because SATB2 is usually negative in neuroendocrine neoplasms of the GI tract, pancreas, and lung. More recently, it has been reported that SATB2 is a sensitive marker for tumors with osteoblastic differentiation.
-
UniProt
- Q9UPW6
Target
-